IDH1 and central nervous system cancer: Although the therapeutic benefit of targeting mutated IDH (mIDH) in gliomas remains controversial [7,8], numerous mIDH-selective inhibitors have been developed to date and in many cases shown to effectively suppress 2-HG production in patients or preclinical tumor models [3,9,10].